Compare NN & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NN | CLDX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | N/A | 1995 |
| Metric | NN | CLDX |
|---|---|---|
| Price | $12.68 | $35.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $25.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | N/A | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $10.87 | $19.72 |
| 52 Week High | $24.42 | $40.30 |
| Indicator | NN | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 51.99 |
| Support Level | $11.62 | $28.51 |
| Resistance Level | $13.58 | $40.30 |
| Average True Range (ATR) | 1.07 | 1.54 |
| MACD | -0.17 | -0.49 |
| Stochastic Oscillator | 6.03 | 37.42 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.